{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SPD489+%28Lisdexamfetamine+dimesylate+%29", "query": { "intervention": "SPD489 (Lisdexamfetamine dimesylate )" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 29, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SPD489+%28Lisdexamfetamine+dimesylate+%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-10T07:13:06.981Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01760993", "title": "Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "SPD489", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 2, "start_date": "2013-02-01", "completion_date": "2013-04-01", "has_results": true, "last_update_posted_date": "2021-06-22", "last_synced_at": "2026-10-10T07:13:06.981Z", "location_count": 2, "location_summary": "Oklahoma City, Oklahoma • Philadelphia, Pennsylvania", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01760993" }, { "nct_id": "NCT02466386", "title": "Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Attention Deficit Hyperactivity Disorder (ADHD)" ], "interventions": [ { "name": "SPD489", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "5 Years", "sex": "ALL", "summary": "4 Years to 5 Years" }, "enrollment_count": 113, "start_date": "2015-08-21", "completion_date": "2020-01-03", "has_results": true, "last_update_posted_date": "2021-03-05", "last_synced_at": "2026-10-10T07:13:06.981Z", "location_count": 50, "location_summary": "Dothan, Alabama • Little Rock, Arkansas • Imperial, California + 41 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Imperial", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02466386" }, { "nct_id": "NCT00697515", "title": "Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ADHD" ], "interventions": [ { "name": "LDX", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 142, "start_date": "2008-07-18", "completion_date": "2008-12-20", "has_results": true, "last_update_posted_date": "2021-06-09", "last_synced_at": "2026-10-10T07:13:06.981Z", "location_count": 5, "location_summary": "Little Rock, Arkansas • Irvine, California • Overland Park, Kansas + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Irvine", "state": "California" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00697515" }, { "nct_id": "NCT01738698", "title": "Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "SPD489 40mg", "type": "DRUG" }, { "name": "SPD489 100mg", "type": "DRUG" }, { "name": "SPD489 160mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 4, "start_date": "2012-11-01", "completion_date": "2013-04-01", "has_results": true, "last_update_posted_date": "2021-06-22", "last_synced_at": "2026-10-10T07:13:06.981Z", "location_count": 1, "location_summary": "Irving, Texas", "locations": [ { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01738698" }, { "nct_id": "NCT01457339", "title": "Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "SPD489 (Lisdexamfetamine dimesylate)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 31, "start_date": "2011-10-21", "completion_date": "2012-01-20", "has_results": true, "last_update_posted_date": "2021-06-03", "last_synced_at": "2026-10-10T07:13:06.981Z", "location_count": 2, "location_summary": "Glendale, California • Long Beach, California", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01457339" }, { "nct_id": "NCT01552902", "title": "Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Attention-deficit/Hyperactivity Disorder" ], "interventions": [ { "name": "Lisdexamfetamine dimesylate", "type": "DRUG" }, { "name": "Methylphenidate Hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "13 Years to 17 Years" }, "enrollment_count": 549, "start_date": "2012-04-03", "completion_date": "2014-05-22", "has_results": true, "last_update_posted_date": "2021-06-10", "last_synced_at": "2026-10-10T07:13:06.981Z", "location_count": 81, "location_summary": "Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 68 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Colton", "state": "California" }, { "city": "Imperial", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01552902" }, { "nct_id": "NCT01274221", "title": "Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ADHD" ], "interventions": [ { "name": "SPD489", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "13 Years to 17 Years" }, "enrollment_count": 0, "start_date": "2011-03-06", "completion_date": "2011-05-04", "has_results": false, "last_update_posted_date": "2021-06-03", "last_synced_at": "2026-10-10T07:13:06.981Z", "location_count": 6, "location_summary": "Little Rock, Arkansas • Bradenton, Florida • Overland Park, Kansas + 3 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01274221" }, { "nct_id": "NCT01760889", "title": "SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "SPD489 low dose range (40mg, 80mg, and 100mg)", "type": "DRUG" }, { "name": "SPD489 high dose range (120mg, 140mg and 160mg)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1, "start_date": "2013-02-01", "completion_date": "2013-04-01", "has_results": true, "last_update_posted_date": "2021-06-22", "last_synced_at": "2026-10-10T07:13:06.981Z", "location_count": 4, "location_summary": "Miami Springs, Florida • O'Fallon, Missouri • Saint Charles, Missouri + 1 more", "locations": [ { "city": "Miami Springs", "state": "Florida" }, { "city": "O'Fallon", "state": "Missouri" }, { "city": "Saint Charles", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01760889" }, { "nct_id": "NCT01101022", "title": "Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "ADHD Specifically With Executive Function Impairment" ], "interventions": [ { "name": "SPD489", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 161, "start_date": "2010-05-19", "completion_date": "2010-11-29", "has_results": true, "last_update_posted_date": "2021-06-09", "last_synced_at": "2026-10-10T07:13:06.981Z", "location_count": 39, "location_summary": "Little Rock, Arkansas • Rolling Hills Estates, California • San Diego, California + 34 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01101022" }, { "nct_id": "NCT01436162", "title": "Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Antidepressant + SPD489 (Lisdexamfetamine dimesylate )", "type": "DRUG" }, { "name": "Antidepressant + Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1105, "start_date": "2011-10-19", "completion_date": "2013-12-10", "has_results": true, "last_update_posted_date": "2021-06-09", "last_synced_at": "2026-10-10T07:13:06.981Z", "location_count": 36, "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Costa Mesa, California + 31 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Downey", "state": "California" }, { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01436162" } ] }